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Foreseeing Super-Response to
Cardiac Resynchronization
Therapy
A Perspective for Clinicians*
Kenneth A. Ellenbogen, MD, Jose F. Huizar, MD
Richmond, Virginia
Current American Heart Association/American College of
Cardiology/Heart Rhythm Society guidelines (1) recom-
mend cardiac resynchronization therapy (CRT) to patients
with symptomatic heart failure (HF) New York Heart
Association (NYHA) class III and IV in patients with wide
QRS (120 ms) and systolic left ventricular (LV) dysfunc-
tion (LV ejection fraction [LVEF] of 35%). Its benefits
are well known, including LV remodeling, decrease in HF
symptoms and hospitalizations, and decreased mortality.
Most recently, the REVERSE (Resynchronization Reverses
Remodeling in Systolic LV Dysfunction) (2) and MADIT-
CRT (Multicenter Automatic Defibrillator Implantation Trail
With Cardiac Resynchronization Therapy) (3) trials demon-
strated additional benefits of CRT in NYHA class I to II.
See page 2366
Unfortunately, the degree of response to CRT varies
among patients. Right bundle branch block, ischemic
cardiomyopathy (CM), NYHA class IV HF, chronic
renal failure, diabetes mellitus, increased levels of brain
natriuretic peptide, severe mitral regurgitation, and ad-
vanced age have been associated with poorer outcomes
after CRT with defibrillator implantation (4–7). In
ontrast, CRT responders and super- or hyper-
esponders (based on improvement of LVEF and LV
imensions) have been found to have an improved
utcome and survival benefit (8–10). Unfortunately,
linical studies to identify predictors of CRT response
nd super-response in symptomatic class II to IV HF
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Biotronik and St. Jude Medical.have shown variable results (Tables 1 and 2). The
discrepancy between different studies can best be ex-
plained by the wide range of criteria (up to 17 criteria) to
define CRT response and super- or hyper-response (11).
In this issue of the Journal, Hsu et al. (12) reported the
predictors that may forecast CRT super-response in
NYHA class I to II HF from the MADIT-CRT trial.
The present study is welcome—it is the largest and most
carefully analyzed patient cohort providing invaluable
information to clinicians about CRT response.
Predictors of CRT response. Most prior studies have
found that nonischemic CM (NICM), left bundle branch
block (LBBB), baseline wider QRS, and smaller LV
dimensions seem to predict CRT response; however,
some predictors may not translate into improved survival
(10,13). Female sex has been noted to be a potential
predictor of CRT response; however, the prevalence of
NICM and LBBB appears to be higher in women than
men (10). In addition, echocardiographic parameters of
dyssynchrony have failed to predict CRT response when
studied in the PROSPECT (Predictors of Response to
CRT) trial (14), mainly attributed to a high interobserver
and intraobserver variability of these parameters. Re-
cently, Goldenberg et al. (15) reported 7 predictors of
echocardiographic CRT response (defined as percent
reduction in LV end-diastolic volume after 1 year of
CRT) in the MADIT-CRT trial (NYHA class I to II),
which included female sex, nonischemic origin, LBBB,
QRS 150 ms, prior hospitalization for HF, LV end-
diastolic volume 125 ml/m2, and left atrial volume 40
ml/m2 (15). They proposed a 0- to 14-point response
score based on these 7 factors, with a risk reduction of
HF or death with CRT of 69%, 36%, and 33% for the
upper (9 points), third, and second quartiles, respec-
tively; without significant risk reduction in the first
quartile (4 points).
Predictors of super- or hyper-response to CRT. Prior
clinical studies in patients with symptomatic HF have
reported an incidence of 10% to 29% of CRT “hyper-” or
“super-”responders (commonly defined as LVEF50% and
functional recovery NYHA class I or II) after 6 months of
CRT. Serdoz et al. (16) reported that NICM, baseline QRS
150 ms, and QRS shortening 40 ms during CRT had a
75% probability of restoration of normal LVEF in NYHA
class III to IV. Most predictors of super- or hyper-
responders (Table 2) are not different than those predictors
of overall CRT response (Table 1). Only duration of HF
symptoms and CM diagnosis has been reported to identify
hyper-responders (9,17).
In this issue of the Journal, Hsu et al. (12) reported for
the first time the predictors of CRT super-responders
(highest quartile of LVEF change after CRT implant) in
asymptomatic NYHA class I to II HF after 6 months of
CRT, which included female sex, lack of prior myocardial
not spe
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index 30 kg/m2, and smaller left atrial volume index.
Most of these predictors are similar to those reported to
predict overall CRT response in the same MADIT-CRT
population (NYHA class I and II) (15), except for body
mass index and left atrial volume index. A lower inci-
dence of primary (HF admission and all-cause death) and
secondary (all-cause death or implantable cardioverter
defibrillator therapy) endpoints was found in the super-
responders group, and these predictors may stratify for
better outcomes and survival (3). The time frame of
super- or hyper-response to CRT has been variable
among patients in prior reports (usually between 3 and 6
Large Clinical Studies (>99 Patients) Assessing Predictors of CRTTable 1 Large Clinical Studies (>99 Patients) Assessing Predi
First Author/
Trial (Ref. #) n
Inclusion Criteria
NYHA Functional
Class EF, % QRS, ms
Lecoq (20) 139 III–IV 35 150 or 200
if paced
LVE
Achilli (21) 133 II–IV 35 QRS 150 ms or in
and intraventr
MIRACLE and
MIRACLE ICD (22)
537 III–IV 35 130 LVE
MIRACLE and
MIRACLE ICD (7)
776 III–IV 35 130 LVE
Yeim (23) 100 III–IV 35 120
Mollema (24) 242 III–IV 35 120
PROSPECT (14) 498 III–IV 35 130
Buck (25) 174 III–IV NS NS
Rickard (26) 99 II–IV 35 120 Non
MADIT-CRT (15) 1,761 I–II 30 129 ICM
N
PROSPECT-ECG (13) 426 III–IV 35 130
QRS  difference between CRT and pre-implant QRS width; 6MWH  6-min hall walk; ACE  a
class, HF admission, and patient global assessment); CRT  cardiac resynchronization therapy;
LBBB  left bundle branch block; LV  left ventricular; LVEDD  LV end-diastolic diameter; LVEDV
end-systolic volume; MD, mechanical dyssynchrony; NICM  nonischemic cardiomyopathy; NS 
TR  tricuspid regurgitation.months), but complete LVEF recovery has been notedeven after 24 months (18,19). Thus, a single 12-month
follow-up does not allow assessment of the time course of
recovery of LV function.
Obviously, a better understanding of predictors of non-
responders, responders, and super-responders (complete
resolution of LV dysfunction and HF symptoms) after CRT
is needed to achieve better outcomes and decrease unnec-
essary procedures and expenses related to this therapy.
However, the definition of all of these terms should be
further standardized. In the final analysis, the present study
provided confirmation of the concept of an electrical revers-
ible cardiomyopathy and helps clinicians identify features
that predict which patients may expect to demonstrate
ponseof CRT Response
Definition of CRT
Response
Echo
Follow-Up
Results—Predictors of
CRT Responser
0 mm Alive, no HF readmission,
improve 1 NYHA
class (or 10%
increase in peak VO2
and 6MHW)
6 months QRS shortening (QRS)
during CRT
ricular
MD
Improved CCS and
absolute LVEF increase
5%
6 months Smaller LVESD, longer
interventricular MD
5 mm Alive and improve
1 NYHA class
1, 3, and 6
months
Clinical predictors differed
between trials; none
clearly predicted CRT
response
5 mm 10% reduction in
LVEDV
6 months Female sex, baseline
LVEDV, baseline QRS
width, NICM
Improve 1 NYHA class
and lack of HF
admission
6 months NICM, wider baseline QRS
width, QRS shortening
during CRT
Improvement 1 class
or 10% reduction in
LVESV
6 months QRS width was not a
predictor for clinical or
echocardiographic CRT
response
Improved CCS and LVESV
reduction 15%
6 months No echocardiographic
measure of dyssynchrony
predicted CRT response
LVESV reduction 10% 6 months Interlead distance 127
mm, S-L delay 60 ms,
NICM, LVEDD 67 mm,
ACE inhibitor, absence
of TR
LVESV reduction 10% 2 months
(mean 13)
Wider QRS (OR: 1.23 per
10-ms increase)
I–II,
ass II
Echocardiographic
response (percent
reduction in LVEDV)
and response score
12 months Female, NICM, LBBB, QRS
150 ms, prior HF
hospitalization, LVEDV
125 ml/m2, LAV
40 ml/m2
Improved CCS, LVESV
reduction 15%
6 months LBBB morphology, LV
paced QRS width and
QRS shortening (QRS)
sin-converting enzyme; CCS  clinical composite score (13) (all-cause mortality, NYHA functional
jection fraction; HF  heart failure; ICM  ischemic cardiomyopathy; LAV  left atrial volume;
nd-diastolic volume; LVEF  LV ejection fraction; LVESD  LV end-systolic diameter; LVESV  LV
cified; NYHA  New York Heart Association; OR  odds ratio; S-L delay  septal to lateral delay;Resctors
Othe
DD 6
tervent
icular
DD 5
DD 5
-LBBB
class
ICM cl
ngioten
EF  e
 LV eremarkable improvements from CRT.
mtrial vol
a
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